Delivery Order SPE2DR25D1201-SPE2DR26FAJRS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,953.33 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL, a biologic immunosuppressant medication used to treat autoimmune conditions. The contract is a firm fixed-price delivery order with an ultimate completion date of September 24, 2025, and was awarded on a competitive, non-set-aside basis. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 12, 2025, for the supply of Humira (Adalimumab) prefilled pens at 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This firm fixed-price delivery order, valued at $5,264.52, represents a non-competitive set-aside award and is scheduled for completion by November 13, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $1,132.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune inflammatory conditions. The delivery order, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, was issued without a set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a $4,852.12 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. This competitively awarded, firm fixed-price contract is a non-set-aside delivery order with an ultimate completion date of November 4, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract represents a child order under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency has awarded a delivery order valued at $2,022.32 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic medication commonly used to treat autoimmune and inflammatory conditions. This competitively awarded, firm fixed-price delivery order was issued on November 20, 2025, with an ultimate completion date of November 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $13,075.97 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) prefilled pens, 40 mg/0.4 mL dosage. This contract is a firm fixed price delivery order with an ultimate completion date of August 5, 2025, and represents a non-set-aside competitive award. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters location. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,907.87 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 80 mg/0.8 mL, a biologic immunosuppressant medication commonly used to treat autoimmune conditions. This firm fixed-price delivery order was awarded on November 20, 2025, with an ultimate completion date of November 21, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive,...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $16,858.64 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL of the immunosuppressant medication. This firm fixed price delivery order, issued on October 27, 2025, with an ultimate completion date of October 28, 2025, was competitively awarded without a set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $1,888.25 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a brand-name biologic pharmaceutical used to treat autoimmune conditions. This competitively awarded, firm fixed-price delivery order was issued on September 11, 2025, with an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. No set-aside designation was applied...
- SPE2DR25D1201Indefinite Delivery Contract
- SPE2DR25D1201-SPE2DR26FAJRSDelivery Order
The Defense Logistics Agency awarded a $1,691.08 delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) prefilled pens containing 40 mg/0.4 mL, a biologic immunosuppressant medication commonly used to treat autoimmune conditions. This non-set-aside, competitively awarded delivery order was issued on November 4, 2025, with an ultimate completion date of November 5, 2025, and carries firm fixed pricing. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor serving federal healthcare systems, AmerisourceBergen leverages this comprehensive global pharmaceutical support vehicle to supply medications and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare organizations. The company's federal contract portfolio demonstrates extensive capability in delivering branded and generic pharmaceuticals across multiple therapeutic domains to support military healthcare requirements worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 11/4/25 |